PPI-Associated Clostridium difficile Infection

Abstract

On reviewing published studies and information from the FDA's Adverse Event Reporting System, the FDA warned the public that use of proton-pump inhibitors (PPIs) may increase the risk for Clostridium difficile –associated diarrhea (CDAD). Although the strength of the association varied widely among studies, most studies found risk for C. difficile infection or disease to be 1.4 to 2.75 times …